Published in Gene Therapy Weekly, May 3rd, 1999
NCI and Affymetrix have agreed that the Affymetrix GeneChip technology will be available to academic and other not-for-profit scientific researchers in a manner that is consistent with the NCI's guidelines for the broad dissemination of research tools and Affymetrix' commercial goals. In particular, researchers will be able to publish scientific results via traditional and emerging...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.